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During the past decades, several discoveries have established the role of epigenetic
modifications and cellular microenvironment in tumor growth and progression. One of the
main representatives concerning epigenetic modification is the polycomb group (PcG).
It is composed of different highly conserved epigenetic effector proteins preserving,
through several post-translational modifications of histones, the silenced state of the
genes implicated in a wide range of central biological events such as development, stem
cell formation, and tumor progression. Proteins of the PcG can be divided in polycomb
repressive complexes (PRCs): PRC1 and PRC2. In particular, enhancer of zeste homolog
2 (EZH2), the catalytic core subunit of PRC2, acts as an epigenetic silencer of many tumor
suppressor genes through the trimethylation of lysine 27 on histone H3, an essential
binding site for DNA methyl transferases and histone deacetylases. A growing number
of data suggests that overexpression of EZH2 associates with progression and poor
outcome in a large number of cancer cases. Hypoxia inducible factor (HIF) is an important
transcription factor involved in modulating cellular response to the microenvironment
by promoting and regulating tumor development such as angiogenesis, inflammation,
metabolic reprogramming, invasion, and metastatic fate. The HIF complex is represented
by different subunits (α and β) acting together and promoting the expression of
vascular endothelial growth factor (VEGF), hexokinase II (HKII), receptor for advanced
glycation end products (RAGE), carbonic anhydrase (CA), etc., after binding to the
hypoxia-response element (HRE) binding site on the DNA. In this review, we will try to
connect these two players by detailing the following: (i) the activity and influence of these
two important regulators of cancer progression in particular for what concerns pediatric
tumors, (ii) the possible correlation between them, and (iii) the feasibility and efficiency to
contrast them using several inhibitors.
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INTRODUCTION
During the past decades, a growing number of scientific data has led to the discovery of epigenetics,
defined as the changes during the development of an organism that are not related to DNA
sequences. Changes in the chromatin configuration at the gene promoter influenced by chemical
modification such as acetylation, methylation, ubiquitylation, and phosphorylation are part of
an exact mechanism that regulates the accessibility to DNA and the consequent transcription
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and expression of coding genes (1). Some of these modifications
are considered inheritable in plants, invertebrates, and also
vertebrates both cell division and cell generation (germline). In
fact, environmental pressures as well as lifestyle can produce
epigenetic changes that can be maintained through two or three
generations even in the absence of the specific stimulus (2).
However, epigenetic modifications, unlike genetic mutations, are
reversible because they fail to alter the nucleotide sequence.
One of the most important epigenetic regulators is
represented by the polycomb group (PcG) of proteins influencing
the expression of many genes implicated in the development
of the organism from childhood to adulthood. Moreover, the
PcG represents evolutionarily conserved multiprotein repressive
complexes such as polycomb repressive complex 1 (PRC1)
and PRC2. In particular, histone methyltransferase enhancer
of zeste homolog 2 (EZH2), a specific component of PRC2,
regulates the trimethylation of Lys 27 on histone 3 (H3K27)
implicated in the expression of some essential genes in the early
steps of X-chromosome inactivation in women (3). Moreover,
deregulation of this particular complex has been associated with
a large number of tumors, and the expression of PcG proteins is
closely associated with carcinogenesis (4).
The development of a tumor is a complicated process in which
a large number of influencers play their own role. The correlation
between tumors and microenvironment was hypothesized in the
last century, and it was part of Stephen Paget’s (1889) “seed
and soil” theory Paget’s 1889 “seed and soil” theory postulating
that metastatic cells of a specific cancer (“the seed”) usually
metastasize to some sites (“the soil”) depending on the affinity
between initial and secondary tumor sites (5).
Nowadays, we know that particular conditions of the hypoxic
tumor microenvironment could promote the expression of
specific oncogenes resulting in the progression of cancer. One of
the most important factors regulating the response of tumor cells
to hypoxia is represented by hypoxia-inducible factor 1 (HIF-1)
(6, 7).
Tumor environment is characterized by the lack of
oxygen, and the cells are exposed to hypoxia. In this specific
hypoxic “habitat,” HIF-1 is activated. Specifically, HIF-1 is
a heterodimeric protein composed of two subunits: HIF-
1β (constitutively expressed) and HIF-1α (O2-regulated).
Under normoxic conditions, the newly synthesized HIF-1α is
hydroxylated at proline residues 402 and/or 564 by specific
prolyl hydroxylase domain (PHD) proteins (i.e., PHD2) using
O2 and α-ketoglutarate as substrates to catalyze a dioxygenase
reaction. During such a reaction, one oxygen is inserted into
the proline residue while the other oxygen is inserted into
α-ketoglutarate leading to the formation of succinate and CO2.
Next, the protein OS-9 interacts with both PHD2 and HIF-1α,
promoting hydroxylation. This step is essential to bind the
von Hippel-Lindau protein (VHL) that, in turn, interacts with
elongin C forming a ubiquitin ligase complex. This process
leads to the proteasomal degradation of HIF-1α. Contrastingly,
under hypoxia conditions, oxygen (O2) deprivation inhibits
the hydroxylation reactions and/or increases the mitochondrial
production of reactive oxygen species (ROS), which oxidize the
ferrous ion in the catalytic site of hydroxylases, thereby inhibiting
these enzymes. In this way, the stability and the transactivation
function of HIF-1α are increased, promoting dimerization with
HIF-1β. This determines the activation of the complex and the
consecutive binding to the hypoxia responsive element (HRE)
sequence 5′-(A/G)CGTG-3′ in target genes, increasing the
transcription into mRNA (6, 7).
More than 40 different HIF-1 target genes are regulated in this
way. Importantly, these genes regulate crucial cellular processes
such as tumor progression, remodeling of themicroenvironment,
cell proliferation, survival, angiogenesis, glucose metabolism,
and iron homeostasis. Proteins encoded by these genes, such as
vascular endothelial growth factor (VEGF), mediate increased
O2 delivery via the formation of new blood vessels. The
expression of other HIF-1-regulated proteins, such as hexokinase
II (HKII), which catalyzes the first step of glycolysis (8), glucose
transporters (GLUT), and glycolytic enzymes, allow cells to
adapt their metabolism to a specific environment distinguished
by a reduction or lack of oxygen. Finally, the expression of
a third group of gene products may influence the balance
between apoptotic and anti-apoptotic signals that determine cell
survival (9).
EZH2 and Its Inhibitors
Enhancer of zeste homolog 2 is the catalytic subunit of the PRC2,
a highly conserved histone methyltransferase, involved in the
methylation of lysine 27 of histone 3.The overexpression of EZH2
has been correlated with many cancers, such as prostate, breast,
bladder, whereas other kinds of cancer, such as B-cell lymphomas
or other forms of breast cancer, can be promoted by specific
mutations (10). For this reason, EZH2 can be considered as
an interesting target for the development of targeted anticancer
strategies (10).
The PRC2 complex operates as a chromatin and it is expressed
in several organisms from plants to flies modifier, and humans.
It interferes with the transcription of target genes (i.e., silencing
genes involved in differentiation) by trimethylating lysine 27
on histone 3 (H3K27me3), considered as its major function “in
vivo.” The human PRC2 complex is composed of five different
subunits: EZH2, SUZ12, EED, AEBP2, and RbAp46/48 (10–12).
In addition, EZH2, which represents the main subunit of PRC2
sequentially catalyzes three methylation reactions at H3K27,
generating monomethylated, dimethylated, and trimethylated
H3K27 (H3K27me1, H3K27me2, and H3K27me3). In the PRC2
complex, EZH2 represents the most important subunit, SUZ12
and EED are important for maintaining the integrity of the entire
structure, while AEBP2 is necessary to stabilize the structure of
the complex. Mutations of these subunits could determine a lack
of PRC2 function. In contrast, the RbAp48 subunit does not seem
to be necessary during the enzymatic activity, and therefore it
may be not essential for the histone methyltransferase action of
EZH2 (12).
Given its specific activities, EZH2 can be considered as an
interesting target in several types of cancer. For this reason,
during the past years, a large number of EZH2 inhibitors
have been discovered, such as 3-deazaneplanocin A (DZNep),
EPZ005687, EI1, GSK126, or UNC1999 (Figure 1). Obviously,
the development of these inhibitors is limited to those cancers
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FIGURE 1 | EZH2 inhibitors 3-deazaneplanocin A (DZNep), EPZ005687, EI1, GSK126, and UNC1999. DZNep is a S-adenosylhomocysteine hydrolase inhibitor,
depletes EZH2 and the associated H3K27me3, and induces apoptosis in breast and colon cancer cells. EPZ005687 inhibits H3K27 methylation by the EZH2 mutants
Y641 and A677, and it has been shown to selectively kill lymphoma cells that are heterozygous for one of these EZH2 mutations. EI1 is active against different forms
of EZH2, while GSK126 effectively inhibits the proliferation of the protein mutants in DLBCL cell lines. UNC1999 represents the first orally bioavailable EZH2 inhibitor.
in which there is a gain of function of EZH2. Therefore, in
this section, we describe different types or tumors indicating,
when possible, the state of EZH2 (wild type, overexpressed,
mutated but still targetable by inhibitors or mutated with a loss of
function). The readermust keep inmind that EZH2 inhibitors are
useless or even harmful in those cancers characterized by a loss of
function of EZH2. Nonetheless, this knowledge is important for
both scientists as well as patients.
The drug DZNep is an S-adenosylhomocysteine hydrolase
inhibitor that reduces EZH2 and H3K27me3 levels, thereby
inducing apoptosis in breast and colon cancer cells. This
compound alters the PRC2 pathway even if the exact mechanism
is yet to be elucidated, but it is considered as a promising drug
for future cancer therapies. The drug EPZ005687 was discovered
as an inhibitor with a 50 fold higher selectivity for EZH2 than
for EZH1 (10). Moreover, EPZ005687 can also inhibit H3K27
methylation induced by two EZH2 mutants (Y641 and A677),
thereby killing lymphoma cells carrying the Y641 or A677 EZH2
mutant (10, 13). In addition, EI1 is active against different forms
of EZH2, while the most potent inhibitor of EZH2, GSK126,
is effective in inhibiting proliferation of the protein mutants in
DLBCL cells (10). The drug UNC1999 an analog of GSK126,
represents the first orally bioavailable EZH2 inhibitor. In vitro
UNC1999 has shown high efficiency against wild type andmutant
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EZH2 against many epigenetic and non-epigenetic targets. In
cells, UNC1999 seems to reduce H3K27me3 levels (IC50<50
nmol/L) reducing the vitality of DLBCL cell lines with the
Y641N mutation (14). Recent genetic studies in a wide range of
organisms have shown an evolutionarily conserved antagonistic
relationship between polycomb proteins and switch/sucrose non-
fermentable (SWI/SNF) complexes, which utilize the energy of
ATP hydrolysis for chromatin remodeling. These complexes
are composed of 12 to 15 subunits that are mutated in 20%
of all human cancers. Moreover, in several cases, it has been
demonstrated that EZH2 gain-of-function mutations such as in
A687 and A677 can lead to cellular transformation as reported in
non-Hodgkin lymphomas(15, 16). Unopposed EZH2 activity is
also a driver of cancers determined by the loss of the core subunit
SNF5/SMARCB1 in the SWI/SNF complex as demonstrated in
rhabdoid tumor, a highly malignant aggressive type of pediatric
cancer (17, 18). Additionally, EZH2 has been shown to also
possess non-enzymatic functions, leading to a situation that
raises the possibility that the enzymatic inhibitors currently
employed in clinical trials may not fully suppress EZH2 activity
as well as its tumor promotion. However, this effect may be
reduced by blocking the interaction between EZH2 and other
PRC2 subunits using a peptide known as stabilized alpha-helix of
EZH2 (SAH-EZH2) obtained from the EZH2 domain interacting
with the EED subunit. The SAH-EZH2 interaction interferes with
the EZH2–EED complex, reducing EZH2 levels, and stopping
H3K27 trimethylation. This peptide is effective against EZH2-
dependent MLL–AF9 leukemia and EZH2-mutant lymphoma
cells, whereas it does not have any effect on non-transformed
and EZH2 controls. Remarkably, the anti-proliferative effect of
SAH-EZH2 has been linked more to the reduction of EZH2
expression than to H3K27me3 reduction. These results are
consistent with the observations stressing the important role
of the non-enzymatic function of EZH2 in SWI/SNF-mutant
cancers (11).
HYPOXIA MASTER REGULATOR HIF-1
AND ITS INHIBITORS
During recent years, a growing number of evidence has
laid the groundwork for a better comprehension of all the
complicated processes implicated in the development of cancers.
Transforming cells are characterized by an uncontrolled growth
forming the tumor mass, and in the internal core, the reduction
of oxygen induces a great number of cellular modifications
leading the cells to adapt to this particular microenvironment. All
these hypoxia-adaptive changes include the switch from oxidative
phosphorylation to glycolysis in cell metabolism, an augmented
synthesis of glycogen, and a switch from glucose to glutamine
as a substrate for the synthesis of fatty acids. In this particular
condition, HIF-1 acts as a primary controller of a great number
of proteins implicated in a wide variety of cellular activities.
The presence of hypoxic regions inside the tumor results in
(I) necrosis of cells distant from vessels of host tissue and (II)
activation of the HIF-1 complex in an attempt to increase the
survival of sublethally damaged tumor cells. In this situation,
HIF-1 expression increases not only the survival of tumor cells
but also their commitment to malignancy (19). In cancer cells,
HIF-1 can also be activated by loss of function of the tumor
suppressor VHL and by gain of function of oncogenes leading
to the activation of the PI3K/AKT/mTOR pathway. Moreover,
HIF-1 activation regulates the metabolism to increase cancer
progression and resistance to therapy. For this reason, HIF-1 or
metabolic enzyme inhibitors may be used to target the metabolic
flexibility of cancer cells increasing their sensitivity to anticancer
therapies (20).
During the past years, a growing number of molecules have
been demonstrated to inhibit HIF-1 activity. A large number
of these inhibitors work by reducing HIF-1α mRNA or protein
levels, HIF-1 DNA-binding activity, or the trans-activation of
some HIF-1 related genes. These drugs reduce the expression of
HIF-1α operating on the synthesis or degradation of proteins.
In many cancers, the synthesis of HIF-1α is strictly related to
mTOR activity. In fact, in cancer cells, the continuous activation
of tyrosine kinase receptors (such as HER2neu, BCR-ABL,
and EGFR) and/or of the downstream phosphatidylinositol 3-
kinase/AKT and RAS/MAP kinase signal transduction pathways
determines the growth of mTOR activity and the consecutive
activation of HIF-1. Thus, inhibitors of these pathways are able to
determine the loss of HIF-1 activity and other biological activities
such as a reduction of tumor vascularization promoting the
therapeutic effect (21).
Moreover, HIF-1 expression can be also controlled by redox
(reduction-oxidation)-dependent processes. In fact, it has been
demonstrated that by treating purified HIF-1 with diamide,
hydrogen peroxide, or N-ethyl-maleimide, a specific alkylator of
cysteine sulfhydryl groups, it is possible to cause a complete loss
of DNA binding activity (22).
On the basis of these data, it is obvious to consider HIF-1
as an important target for anticancer therapy, and during the
past years, several natural products (generally, the term “natural
product” is used to indicate low molecular weight secondary
metabolites produced by animals, plants, and microbes for
chemical defense and growth advantage) or synthetic compounds
have been shown to possess an anti HIF-1 activity.
NATURAL INHIBITORS
Several emerging scientific data show the efficacy of many
natural compounds to inhibit the activity of HIF-1 operating
on protein synthesis or protein degradation. Actinomycin
D (dactinomycin) is a metabolite produced by Streptomyces
parvullus (formerly S. antibioticus) that acts as an inhibitor
of transcription, and it is able to block hypoxia-induced HIF-
1 activity in the human hepatoma cell line Hep3B. Moreover,
other data showed the efficacy of actinomycin D to block
HIF-1α induction by angiotensin II (Ang II) in the vascular
smooth muscle cells of rats without altering hypoxia induction.
Inhibition of HIF-1 depended on the cell type, stimulus,
and drug concentration. Another cytotoxic compound, GL331,
is a semisynthetic podophyllotoxin-derived topoisomerase II
inhibitor with IC50 values in the range of 0.5µm to 2µm that
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has been shown to work against a large number of tumor cell
lines. In the human lung adenocarcinoma cell line CL1-5, using
a concentration of 10µm of GL331, it has been possible to
decrease HIF-1α mRNA levels, probably through transcriptional
inhibition. However, such an inhibitory effect is not specific
for HIF-1. At the same concentrations, the compound shows
cytotoxicity and inhibits the expression of cyclin D1 in CL1-5
cells. In addition, GL331 demonstrated no effects against gastric
cancer in a clinical study (23).
Emerging data have discovered a growing number of natural
products capable of reducing HIF-1α mRNA levels despite the
fact that the mechanism is not completely clear for all of them.
The Indian traditional medicine glycoside known as picroliv (in
which the major compound found is a purified iridoid glycoside
fraction picroside-I and kutkoside from the roots of Picrorhiza
kurrooa) reduced HIF-1α and VEGF mRNA levels in vitro (24,
25).
Other compounds have the ability to promote HIF-1
degradation through different ways. For example, geldanamycin
(GA), a metabolite of Streptomyces hygroscopicus, interferes with
hsp90 through the amino-terminal ATP/ADP binding pocket.
In addition, GA blocks the activation of the HIF-1 complex
promoting the degradation of the α-subunit through a VHL-
independent proteasomal mechanism both in normoxic and
hypoxic conditions (26, 27).
Other emerging scientific data have shown that by using the
antifungal antibiotic cycloheximide isolated from Streptomyces
griseus, it is possible to inhibit general eukaryotic protein
synthesis and to interfere with the accumulation and
activation of the HIF-1α protein. Another important group
of compounds with inhibitory effects on HIF-1α protein
synthesis is represented by microtubule disrupting agents
(MDA) (23). Additionally, other hsp90 inhibitors such as
17-N-allylamino-17demethoxygeldanamycin, resveratrol,
the antibiotic novobiocin, and many others have been
shown to have an activity against the accumulation of HIF-1
(23).
Finally, another natural compound with an anti HIF-1 activity
is the red Korean ginseng, even if the mechanisms of action and
the antitumor effect are yet to be clarified (19, 28).
Therefore, as reported in this review, there are several natural
drugs and compounds capable of interfering with HIF-1 activity,
accumulation, and function, and this can possibly lead to the
development of new anticancer strategies in the future (Figure 2).
However, even if a growing number of evidence is collected day
by day, still several sets of data are necessarily required to go on
in this way.
HIF–EZH2: TWO SIDES OF THE SAME
COIN?
During the past years, great progresses have been made in many
areas of pediatric oncology even if tumors of the central nervous
system (CNS) remain a significant challenge because of their
complicated nature. Basing on recent scientific data, it has been
possible to achieve a better comprehension of cancer molecular
mechanisms and to develop new therapeutic approaches focused
on different molecules and pathways (Figure 3).
In this review, we paid particular attention on some specific
pediatric tumors such as high grade glioma and pediatric low
grade glioma.
Pediatric high grade gliomas (pHGGs) have the same
histological, but not molecular, features of adult HGGs (aHGGs)
and have been classified, in accordance with the World Health
Organization (WHO), as grade III and IV CNS tumors. Grade III
glioma (anaplastic astrocytoma) is characterized, histologically,
by atypical nuclei, an increased cellularity, and an increased
mitotic activity. Grade IV glioma, also known as glioblastoma
multiforme (GBM), is the most pathologically advanced and
clinically aggressive tumor. A wide number of genomic analyses
on several pediatric tumors such as glioblastomas, anaplastic
astrocytomas, and diffuse intrinsic pontine gliomas (DIPG) have
revealed frequent mutations of the H3F3A gene (29) (encoding
H3.3) in which the lysine residue at position 27 was substituted
with a methionine (K27M) or the glycine residue at position
34 with an arginine or valine (G34R/V) (30–33). Conversely,
just a limited number of DIPGs revealed a replacement of
the lysine residue at position 27 with a methionine (K27M)
in the HIST1H3B gene encoding for the histone H3.1 (33).
In fact, pediatric GBM with H3F3A K27M mutations shows
a reduction in H3K27me3 when compared with wild type
tumors. Moreover, anaplastic astrocytomas also revealed the
presence of a significant fraction of hypoxic tissue areas. In
fact, hypoxia has been shown to play an important role in the
malignant progression of various tumor entities, and hypoxic
areas have been found in malignancies such as breast, prostate,
pancreas, and lung cancer, soft tissue sarcomas, non-Hodgkin’s
lymphomas, melanomas, liver tumors, etc (34). Hypoxia leads
to the activation of HIF-1 via the stabilization of its α-subunit.
Importantly, a number of studies have indicated a widespread
expression of HIF-1α (35–39) and its target genes glucose
transporter (GLUT)-1 (40) and carbonic anhydrase (CA) IX (40,
41), in malignant astrocytomas. Hypoxia has been suggested as
an adverse prognostic factor for patient outcome. In fact, several
studies of tumor hypoxia involving the direct assessment of the
oxygenation status have suggested worse disease-free survival for
patients with hypoxic cervical cancers or soft tissue sarcomas. In
head & neck cancers, studies suggest that hypoxia is prognostic
for survival (34). In fact, the identification and quantification
of hypoxic regions is extremely important for the management
of the disease. A large number of predictive assays for tumor
oxygenation status have been developed in the past years showing
differences in the degrees of success. To date, functional imaging
techniques based on positron emission tomography (PET) have
been demonstrated to be fundamental for both pretreatment
and tumor response evaluation during therapy. Several hypoxia-
specific PET markers have been developed in several clinics to
quantify hypoxic tumor sub-volumes for personalized treatment
planning. Moreover, a large number of new radiotracers are
actually under investigation. In addition, PET-derived functional
parameters and tracer pharmacokinetics can be used to obtain
very useful input data to create computational models aimed to
simulate or interpret PET acquired data to develop new treatment
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FIGURE 2 | Natural inhibitors of HIF-1. During these years, a large number of compounds have been tested, and their natural inhibitory effect during hypoxia has been
demonstrated. Here, we reported some of them presenting different mechanisms of action such as inhibition of transcription, inhibition of VEGF, inhibition of HIF-1
synthesis or dimerization, etc.
planning or radio/chemotherapy response prediction programs
(42).
Primary GBM is characterized by increased vascular
proliferation and necrosis in addition to the features of grade
III glioma (43). In particular, pHGGs have a specific wide
distribution in contrast to aHGGs that are more frequent in
the cerebral cortex (44). Molecularly, pHGGs are distinct from
aHGG and are characterized by a great number of activating
or inactivating gene modifications, such as gene amplifications,
deletions, and inactivation of p53 and histone 3.3 (H3F3A),
causing them to be activated and inactivated (45).
The canonical treatment for pHGG occurring in the
cerebrum typically includes initial surgery followed by radiation
and chemotherapy. There is widespread agreement that total
resection of tumor tissue improves patient outcome, but anyway,
focal radiation therapy has also become standard in the treatment
of patients greater than 3 years of age with pHGG (43).
Chemotherapy is frequently used to treat patients with pHGG;
although evidence of efficacy is modest, chemotherapeutic agents
are often employed in the treatment of these patients in
combination with temozolomide even if the ability of this drug
is still debated (46–48).
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FIGURE 3 | Cancer onset influencing mediators. Cancer represents a multifactorial pathology in which a large number of alterations act to promote the onset and
development. Alterations of EZH2, HIF-1, and mutations of SWI/SNF may provide a negative influence promoting tumors. Curved arrows with question marks refer to
the fact that no data or very little data are available regarding the possible interaction between EZH2 and HIF-1 during cancer onset. On the contrary, thanks to recent
studies, the importance of single treatments with either HIF-1 or EZH2 inhibitors, combined with other therapeutic approaches, to contrast the tumor and to obtain a
therapeutic efficacy has been shown. It would be interesting to try a new approach with inhibitors for both EZH2 and HIF-1.
Medulloblastoma (MB) is another pediatric brain tumor,
representing 15–20% of the tumors occurring at a young age.
While it can occur at any age from infancy through adulthood,
it is most typically seen in children with bimodal incidence peaks
between 3 and 4 or 8 and 9 years of age (49). MB is characterized
by four distinct molecular subgroups, such as those dependent
on Wingless (WNT) or Sonic Hedgehog (SHH) signaling and
those that are less well characterized (Group 3 (G3) and Group
4 (G4)), showing multiple responses to common therapeutic
approaches (50). These tumors present, in contrast to most other
cancers, some recurrent mutations. These four MB subgroups
have different mutational landscape, gene expression, pathology,
and prognosis (50–54). In fact, about 25% of MBs are G3
tumors with high MYC levels as a result of somatic MYC gene
amplification in about 15–20% of G3 cases. Moreover, some G3
MBs have been associated with relatively high levels of EZH2 and
to increased global H3K27me3 chromatin repressive marks (53).
In contrast, the H3K27me3-specific demethylase, KDM6A/UTX,
is mutated in a reciprocally exclusive manner for the most part
in G4 MBs (53, 55–57). Basing on this knowledge, recently,
it has been possible to investigate the relationship between
G3MB and EZH2 and to explore its functional relationship with
other genes that are important for the development of MB,
using gene editing systems. In fact, in this way, it has been
possible to demonstrate that the deletion of EZH2 accelerates
de novo MB development and the progression of established
MBs and that EZH2 inactivation in G3MB implicates Gfi1 (a
proto-oncogene frequently activated in human G3 MBs whose
disruption antagonizes the tumor promoting effects of Ezh2
loss) as an oncogenic target gene. Therefore, enforced expression
of Gfi1 promotes secondary G3MB formation mimicking the
effects of the absence of Ezh2, whereas the lack of Gfi1contrasted
the effects of Ezh2 inactivation, together providing at least a
partial rationale for Ezh2-mediated tumor suppression (58).
Importantly, these new results point the attention to the
complexity of the pathways directly and indirectly influenced
by EZH2 to the point that this protein can function as either
a tumor suppressor or promoter depending on the cellular
context.
Ependymomas occur in both children and adults and can
arise throughout the entire neuraxis. They are divided, according
to the WHO, into three types classified as grade I, II, and
III. While spinal cord tumors are more common in adults, in
pediatric patients, approximately 70% of ependymomas arise in
the posterior fossa. The canonical treatment for these specific
tumors is based mainly on surgical resection, and in the post-
operative period, radiation can be used to improve the survival
frequency (49).
During the pediatric age, other kinds of tumor such as low
grade glioma (PLGG) can cause several problems to patients.
This kind of tumor represents the most common type of
pediatric astrocytoma and pediatric brain tumor in general.
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According to the WHO classification, PLGGs are grade I
or II and include pilocytic astrocytoma (PA), subependymal
giant cell astrocytoma (SEGA), pilomyxoid astrocytoma (PMA),
pleomorphic xanthoastrocytoma (PXA), and low-grade fibrillary
astrocytoma or diffuse astrocytoma. Among these tumors, PA is
considered the most common glioma in children.
Actually, these tumors are treated using different drugs
including carboplatin, vincristine, temozolomide, etc. Anyway,
surgical resection is commonly used to treat subependymal
giant cell astrocytoma especially in the case of intracranial
hypertension.
Apart from pediatric brain tumors, epigenetic alterations
have an important role in several cancers; for example in
leukemias, repressive proteins of the polycomb group, PRC1 and
PRC2, are the main epigenetic regulators in developmental and
transcriptional repression.
For example, early T cell precursor acute lymphoblastic
leukemia (ETP-ALL) represents an aggressive subtype
of ALL characterized by the presence of stem cells and
transcriptional programs observed in myeloid cells (59). It has
been demonstrated that inactivating alterations of the PRC2
components are recurrent in this kind of human tumor, but
their functional role is yet to be entirely defined (60). Some
data about the involvement of EZH2 have been collected using
a murine model of NRASQ61K-driven leukemia that shows
the phenotypic and transcriptional aspects of ETP-ALL (60).
In particular, homozygous inactivation of EZH2 cooperates
with oncogenic NRASQ61K to favor leukemia development. In
addition, EZH2 acts as silencer of stem cell- and early progenitor
cell-associated genes, and its loss is associated with an increased
activation of signal transducer and activator of transcription 3
(STAT3) by tyrosine 705 phosphorylation (60). Moreover, the
activity of STAT3 maintains the co-option of a pro-metastatic
program in activated astrocytes in a metastatic lesion. These
astrocytes support metastatic cells through their ability to
modulate the innate and acquired immune systems, and it has
been demonstrated that patients who have reactive astrocytes
with active STAT3, show a reduced survival from the diagnosis
of intracranial metastases. In fact, if in reactive astrocytes the
signaling of STAT3 is prevented, it is possible to reduce the
formation of metastasis in the brain from different primary
tumor sources. Thus, by using an orally bioavailable treatment
against STAT3, it is possible to obtain an antitumor effect in
patients even with advanced systemic diseases such as brain
metastasis (61).
Therefore, according to these data, the inactivation of EZH2
can be linked to the activation of transcriptional programs
in stem cells and to increased growth/survival signaling,
characteristics determining a poor prognosis in patients (60).
T-cell acute lymphoblastic leukemia (T-ALL) represents about
10–15 % of pediatric ALL cases and, when compared with
B-progenitor ALL patients, shows some aggressive clinical
features such as higher risk for primary resistant disease, and
frequent early isolated central nervous system relapse. In recent
years, thanks to different therapeutic strategies based on intensive
chemotherapy, T-ALL prognosis in children and adolescents
has improved. However, it is still worse when compared with
B-lineage ALL in particular if associated to a lack of initial
response to the therapy with prednisone (62). Another approach
to treat this tumor is based on 3-deazaneplanocin-A (DZNep)
blocking EZH2. This agent showed a good activity inducing a
strong apoptosis of cancer cells; however, additional data have to
be collected regarding its potential for treating T-cell ALL (63).
Other therapeutic approaches for the treatment of this cancer
are based on daunoblastine, an anti-leukemic agent used for
decades despite the fact that its success is frequently linked to
the use of other drugs. For this reason, recently, the efficacy
of this drug in combination with DZNep has been shown.
A combination of these drugs in the ratio 25:50 showed a
synergistic effect at the CalcuSyn elaboration (a software to
explore the relative contribution of each agent to the synergism)
and induced apoptosis in Jurkat cells. In particular, DZNep
caused 63 % of apoptosis if used alone, whereas a stronger effect
up to the 67% was observed if combined with daunoblastine
after 72 h of treatment (64). Therefore, DZNep inhibits Jurkat
cell proliferation through the activation of check-points that
block cell cycle arrest at S phase, an effect that results in
the induction of apoptosis. In fact, EZH2 was upregulated in
natural killer/T-cell lymphoma, through Myc-mediated mRNA
inhibition. Such EZH2 upregulation determines the activation of
cyclin D transcription promoting cell proliferation, an effect that
is independent of its methyltransferase activity (65).
Even if the principal activity of EZH2 as a gene silencer
proceeds through the methylation of H3K27, a large number
of studies have shown that the transcriptional activation of
EZH2 in many types of cancer is achieved independently
of H3K27me (66). This activity has been demonstrated
especially in natural killer/T-cell lymphoma, in which cyclin
D transcription is activated by EZH2 upregulation via Myc-
mediated mRNA inhibition promoting cell proliferation without
a methyltransferase activity (65). Similarly, in Jurkat cells,
when EZH2 is upregulated, there is an activation of cyclin
D transcription demonstrating the effect of DZNep. The data
obtained showed that using both agents causes a change in
the expression and activity of several central proteins such as
caspase-3, 9, Bcl-2, Erk, and EZH2. Specifically, a reduction
of Bcl-2 and an increase of cleaved caspase-3 and caspase-
9 especially in cells treated with therapy combination has
been observed. Moreover, the combination also inhibited Erk-
mediated proliferation pathway. This observation has been
considered extremely important since it gives the possibility to
develop new therapeutic approaches based on the combination
of DZNep and daunoblastine to treat T-ALL cells, in particular
the subgroup with a much worse prognosis (63).
Along with PRC2, another main factor promoting the
development and progression of cancer is represented by the
microenvironment and its main responder HIF even for what
concerns pediatric tumors. In fact, several studies reported a
large number of brain and non-brain tumors in which HIF
plays a primary role (39, 67–69). One example is that of
metformin, a well-known insulin-sensitizer frequently used for
type 2 diabetes therapy, which can be potentially considered
as a very interesting drug in oncology also. In fact, the use of
metformin has been hypothesized to contrast pediatric sarcomas
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such as osteosarcoma, Ewing sarcoma, and rhabdomyosarcoma,
representing common pediatric sarcomas, that depend on
insulin-like growth factor (IGF) and insulin for pathogenesis
and progression. In vitro results showed antiproliferative and
chemosensitizing effects, but these results have not been
confirmed in in vivo experiments related to Ewing sarcoma even
if combined with vincristine. It is suggested that hypoxia, present
in solid tumors, may be the cause of the discrepancy between
in vitro and in vivo effects. In fact, some evidence confirmed
that hypoxia can prevent the antitumoral mechanism of action
of metformin, that is, activation of AMPK and inhibition of
mTOR signaling. Thus, the use of metformin for conventional
chemotherapy may be limited to low hypoxic tumors. For this
reason, the influence of hypoxia should be always considered
when using novel therapies to treat these sarcomas in particular
(67).
As frequently demonstrated, the development and
progression of a tumor is linked to a large number of molecules
and/or to a long sequence of events and modifications leading
to the proliferation of cells. The tumor suppressor gene p53
and its family members p63/p73 are the main regulators
of the cell cycle and critical determinants of tumorigenesis.
1Np63 is a splice variant of p63, which lacks the N-terminal
transactivation domain and acts as an antagonist of p53-,
p63-, and p73- dependent translation, contrasting their tumor
suppressor activity. Recent studies of pediatric neuroblastoma
and osteosarcoma, demonstrated an increased expression
of 1Np63, but it has not been possible to correlate 1Np63
expression with p53 mutation status (70). For this reason, a
possible mechanism leading 1Np63 itself to favor the cells’
malignant transformation with a gain of function independently
by any p53 antagonism has been supposed. The overexpression
of 1Np63, independent of p53, increases the secretion of
interleukin-6 (IL-6) and interleukin-8 (IL-8), leading to the
elevated phosphorylation of STAT3 (Tyr-705). This condition
leads to the stabilization of the HIF-1α protein, resulting
in VEGF secretion. These data suggest that high levels of
1Np63α are expressed in pediatric neuroblastoma and
osteosarcoma, 1Np63α has oncogenic effects in neuroblastoma
and osteosarcoma, 1Np63α regulates VEGF activity and
promotes migration, induces STAT3 phosphorylation, and
increases the transcription of interleukin (IL-6 and IL-8), and
that 1Np63 expression is enhanced in osteosarcoma lung
metastases (70).
As reported for many kinds of tumor, hypoxia plays a primary
role in the development, and progression of the pathology,
influencing the specific microenvironment in which tumor cells
live. One of the most dangerous but also uncommon tumors
with <50 cases reported in literature (71, 72), with a poor cure
of approximately 2 months (72) in infancy even with intensive
therapy, is congenital glioblastoma (cGBM). The prognosis of
this tumor is absolutely poor, but surgery and/or chemotherapy
can increase long-term survival (24–33 months) (72) if the
infants survive birth and initial surgery or biopsy. Histologically,
they are very similar to other GBMs and present themselves
with some typical features such as hypercellularity, high ability
to infiltrate in the glia with necrosis and/or pseudopalisading
necrosis, vascular proliferation, and increased mitotic activity
and MIB-1 rate (72, 73). Following these observations, recently,
it has been carried in a study on five patients with congenital
GBMs in the first 3 months of life. Glioblastomas were situated
in the deep gray matter close to the ventricles, and three of the
patients had an extension of the tumor parenchyma into the
intraventricular space. Four patients survived surgery, but the
tumor was completely removed only in one of them. Cytogenetic
studies on one patient demonstrated the presence of a diploid
population; meanwhile, in two of the three patients, a diploid
clone was observed in combination with aneuploidy in a near
tetraploid context, while in the other, tetraploidy was seen in
combination with diploidy. Furthermore, another interesting
observation of this study is the difference in ploidy between
this tumor and the small cell astrocytoma/GBM. However, FISH
analysis revealed that this tumor type possesses disseminated
diploid populations (74). Hierarchical clustering analysis in
the three cGBMs has shown a similar gene expression also
comparable to other high-grade adult and pediatric gliomas.
Comparing cGBMs with pediatric and adult GBMs revealed
that only 31 genes were differentially expressed. This can be
considered to be, despite the different scale, very similar to
the differences observed between pediatric GBMs and adult
GBMs. Furthermore, in all three cGBM samples measured, EGFR
gene expression was very low, and additionally amplification
in EGFR was not observed, a result very similar to pediatric
GBMs. Moreover, functional analysis showed that more that
50% of the differing genes had a role in signal transduction,
including four receptor tyrosine kinases, and 39% of the differing
genes in cGBMS, were involved in glucose metabolism. Thanks
to these evidence, it has been possible to differentiate cGBMs
from pediatric and adult GBMs. Furthermore, in some cases,
cGBMs may have a better prognosis than pediatric or adult
GBMs, however, this is strongly dependent on the ability of
the infants to survive birth, tolerate surgery, and undergo
chemotherapy. Patients who were exposed to surgery with
subtotal resection or biopsy also did well, suggesting that it is not
necessary to base the therapeutic approach on aggressive surgery
probably inducingmoremorbidity in this population. Since these
tumors are characterized by high vascularization and bleeding,
patients with cGBMs show a good response to moderately
intense chemotherapy regimens without requiring stem cell
rescue or dose-dense chemotherapy to obtain a response. In
conclusion, this study provides important information on a rare
tumor. Unfortunately, such information is limited due to the
small sample size, and for this reason, additional evidence is
necessary to solidify both the molecular and chemotherapeutic
results (75).
HIF–EZH2 CONNECTION
The correlation between HIF-1 and EZH2 is an interesting but
yet uncharted aspect of tumor biology. There are few scientific
studies connecting hypoxia, HIF-1, and EZH2 during tumor
formation or tumor progression. The majority of such studies
concord with the idea that hypoxia in general and HIF-1 in
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particular increase EZH2 expression. In fact, in pancreatic cancer
cells, hypoxia stabilizes HIF-1α that, in turn, increases TWIST
expression. TWIST accumulation increases EZH2 expression and
tumorigenesis measured as epithelial-mesenchimal transition
(EMT) and xenograft growth (76). Similarly, in hepatocellular
carcinoma (HCC), hypoxia and HIF-1α increases NIPP and
EZH2 levels, an effect that then results in augmented invasive
and metastatic potential (77). Interestingly, abrogation of NIPP
and EZH2 expression, prevented such a malignant phenotype
(77).
Another example regarding the correlation between HIF-
1 and EZH2 has been revealed in a study conducted some
years ago in which the expression of EZH2 in breast tumor
initiating cells (BTICs) is enhanced by hypoxia through
HIF1α-mediated transactivation, which promotes the expansion
of BTICs and cancer progression (78, 79). The enhanced
expression of EZH2 in BTICs determines the downregulation
of DNA damage repair proteins and the accumulation of
genomic abnormalities that mediate deregulated signaling
(RAF1-ERK-β-catenin) resulting in BTIC expansion and cancer
progression. Moreover, it has been revealed that the cancer-
predisposed hypoxic microenvironment may promote BTICs
through the upregulation of EZH2 expression. Furthermore,
a specific genomic aberration mediated by EZH2-impaired
DNA damage response has been linked to the expansion of
BTICs and, finally, it has been possible to show a previously
unidentified therapeutic effect of the inhibitors of RAF1-
ERK signaling (e.g., AZD6244, a specific MEK/ERK inhibitor,
already tested in multiple clinical trials) to prevent breast
cancer progression by eliminating BTICs with important clinical
implications (79).
Interestingly, in colorectal cancer, HIF activation is achieved
through the overexpression of the type II Na/Pi co-transporter
SLC34A2 causing ROS accumulation. In fact, increased ROS
stabilize the HIF-1α protein inducing EZH2 overexpression.
The silencing of SLC34A2 completely prevented EZH2
overexpression, as well as colorectal cell proliferation and
chemo-resistance (80). Another mechanism through which
HIF-1α can increase EZH2 expression has been demonstrated
in prostate cancer cells. In these studies, authors show that
HIF-1α activation during hypoxia is accompanied by a
decrease in the expression of miR-101 and the increase of
EZH2 (81). In fact, normally, expression of miR-101 inhibits
EZH2 production and the invasiveness of prostate cancer
cells (81). Upon HIF activation, however, miR-101 levels
drop, thereby increasing EZH2 expression and the invasion
of prostate tumor cells (81). However, the study of the HIF-
EZH2 interplay is complicated by the observation that, in
glioblastoma, EZH2 activates HIF-1α expression by inhibiting
the eleven-nineteen lysine-rich leukemia associated factor
2 (EAF2) that, in the prostate, regulates transcriptional
elongation of RNA Poll II (82). In fact, EAF2 binds and
stabilizes VHL, thereby reducing HIF-1α levels. Therefore,
by decreasing EAF2 expression, EZH2 reduces VHL activity
stabilizing HIF-1α expression, which is an effect that, in
turn, increases tumor growth and metabolism favoring
glycolysis (82).
In addition, in multiple myeloma, EZH2 inactivation upon
phosphorylation is observed during the acquisition of multi
drug resistance. Interestingly, in this tumor, EZH2 inactivation
is accompanied by increased expression of HIF-1α and
anti-apoptotic genes, an effect that then causes multidrug
resistance (83).
Finally, it has been demonstrated that, under hypoxia, HIF-
1α regulates the switch from the tumor suppressive to the
oncogenic function of EZH2. This interesting study tries, for
the first time, to reconcile these two apparently opposing effects
of EZH2 by showing that EZH2 has a tumor suppressive
function when part of the PRC2 and a tumor promoting function
when bound to Forkhead box M1 (FoxM1) by increasing
matrix metalloproteinase expression and tumor cell invasion.
Importantly, HIF-1α regulates the formation of these complexes
by shifting EZH2 from PRC2 to FoxM1. Such an effect is achieved
through an HIF-1α-mediated decrease in the expression of the
PRC2 complex (84). In conclusion, even if scientific evidence
correlates that HIF-1 and EZH2 are accumulating, still there is
a need to obtain more additional data before we can completely
elucidate and connect the mechanisms involving both HIF-1 and
EZH2 in a tumor specific context.
SOMETHING FOR THE FUTURE
During recent years, a large number of scientific studies
revealed the importance of therapeutic targeting of PRC2.
Such a consideration emerged when it was observed that
EZH2 overexpression or mutations increasing EZH2 activity
could initiate, promote, or maintain oncogenesis. Some of
the molecules that have been already developed such as the
small-molecule inhibitors of PRC2 or EZH2 are actually under
clinical evaluation for the treatment of some kinds of cancers
including germinal-center B-cell lymphomas characterized by
EZH2 mutations, which represent about 15–20% of all cases.
PRC2, or more precisely its subunit EZH2, has been implicated in
the development of various hematopoietic drugs. Furthermore,
some drugs that have already been developed could be used to
develop more efficient therapeutic approaches and personalized
therapies.
Basing on this knowledge, it is important to consider the
wide potential of these new generation of drugs not only for the
actual but also for future therapeutic strategies. However, caution
must be taken when planning to use EZH2 inhibitors and in
interpreting the results. In fact, as recently demonstrated, our
knowledge of the role of EZH2 as a tumor suppressor or tumor
promoter is still too limited, and new players and interlinked
pathways must be detailed and studied before we can provide a
valid antitumor strategy that uses inhibitors of EZH2. Moreover,
the use of such inhibitors will be context-specific according to the
role of EZH2 in that specific tumor.
As reported in this review, HIF-1 plays a central role in
tumor growth/progression. In fact, numerous in vitro/in vivo
experiments have demonstrated an inhibition of tumor growth
elicited by many HIF-1 inhibitors at the point to activate
clinical trials for some of them. In particular, 2ME2 and other
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derived-molecules are undergoing phase I and II clinical trials
in patients with breast, prostate, and ovarian cancer (83, 84).
Other drugs such as analogs of GA are employed to treat patients
with VHL disease, breast cancer, etc. in phase II clinical trials
(85, 86). In addition, bortezomib has been approved by the FDA
for multiple myeloma treatment, based on the results from the
phase II trials. Finally, EZN-2968 is currently in phase I clinical
trials (85, 86).
As reported in this review and depicted in Figure 3, both
EZH2 and HIF-1 play major roles in the regulation of cellular
activities, and interference in their normal functions may
alter the cellular homeostasis resulting in the development of
different pathologies such as cancer. Even if little is known, new
experiments that aim to unravel the connection between EZH2
and HIF may lay the groundwork for a better comprehension
of the pathologic molecular mechanisms interlinking these two
molecular players and will provide the possibility to develop,
day by day, an increasing number of specific drugs to use in
personalized therapies against cancer.
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